2,836 Shares in Illumina, Inc. (NASDAQ:ILMN) Purchased by Westfield Capital Management Co. LP

Westfield Capital Management Co. LP bought a new stake in Illumina, Inc. (NASDAQ:ILMN) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 2,836 shares of the life sciences company’s stock, valued at approximately $370,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Freemont Management S.A. acquired a new position in Illumina during the third quarter valued at approximately $1,565,000. Cetera Advisors LLC acquired a new position in shares of Illumina during the 1st quarter worth $610,000. Weybosset Research & Management LLC lifted its position in shares of Illumina by 92.0% during the 3rd quarter. Weybosset Research & Management LLC now owns 18,052 shares of the life sciences company’s stock worth $2,354,000 after buying an additional 8,650 shares during the last quarter. B. Riley Wealth Advisors Inc. boosted its stake in Illumina by 176.3% in the second quarter. B. Riley Wealth Advisors Inc. now owns 7,176 shares of the life sciences company’s stock valued at $749,000 after buying an additional 4,579 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. grew its position in Illumina by 3.6% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 399,966 shares of the life sciences company’s stock valued at $41,748,000 after acquiring an additional 13,725 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Stock Up 2.6 %

Shares of NASDAQ ILMN opened at $143.82 on Tuesday. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. The firm has a market cap of $22.81 billion, a PE ratio of -14.44 and a beta of 1.13. The company’s fifty day simple moving average is $140.90 and its 200 day simple moving average is $125.17. Illumina, Inc. has a 12-month low of $93.51 and a 12-month high of $156.66.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The company had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.08 billion. During the same quarter in the prior year, the firm earned $0.33 EPS. The business’s revenue was down 3.5% on a year-over-year basis. As a group, sell-side analysts forecast that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ILMN has been the subject of a number of research reports. Canaccord Genuity Group increased their target price on shares of Illumina from $130.00 to $145.00 and gave the stock a “hold” rating in a report on Tuesday, November 5th. Citigroup boosted their target price on shares of Illumina from $155.00 to $190.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Robert W. Baird increased their price target on Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Daiwa America raised Illumina to a “strong-buy” rating in a report on Friday, August 16th. Finally, Daiwa Capital Markets raised Illumina from a “neutral” rating to a “buy” rating and upped their target price for the stock from $120.00 to $154.00 in a report on Friday, August 16th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $164.00.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.